Novel treatment avenues for peripheral T-cell lymphomas

Bibliography

• Harris NL, Jaffe ES, Diebold J, World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49
   PubMed Web of Science ®Google Scholar
• Jaffe E, Harris NL, Stein H, Vardiman JW. WHO classification of tumourspathology and genetics of tumours of the haematopoetic and lymphoid tissues. IARC Press; Lyon: 2001
   Google Scholar
• Swerdlow SH, Harris NL, Campo E, WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press; Lyon, France: 2008
   Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30
   PubMed Web of Science ®Google Scholar
• Bishu S, Quigley JM, Schmitz J, F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 2007;48:1531-8
   PubMed Web of Science ®Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, Report of the Committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1
   PubMed Web of Science ®Google Scholar
• Shipp MA, Harrington DP, Anderson JR, A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94
   PubMed Web of Science ®Google Scholar
• Ansell SM, Habermann TM, Kurtin PJ, Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997;15:2296-301
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-9
   PubMed Web of Science ®Google Scholar
• Rizvi MA, Evens AM, Tallman MS, T-cell non-Hodgkin lymphoma. Blood 2006;107:1255-64
   PubMed Web of Science ®Google Scholar
• Barry TS, Jaffe ES, Sorbara L, Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 2003;27:1513-22
   PubMed Web of Science ®Google Scholar
• Went P, Agostinelli C, Gallamini A, Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006;24:2472-9
   PubMed Web of Science ®Google Scholar
• Ishida T, Joh T, Uike N, Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012;30:837-42
   PubMed Web of Science ®Google Scholar
• Iqbal J, Weisenburger DD, Greiner TC, Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010;115:1026-36
   PubMed Web of Science ®Google Scholar
• Bal M, Gujral S, Gandhi J, Angioimmunoblastic T-Cell lymphoma: a critical analysis of clinical, morphologic and immunophenotypic features. Indian J Pathol Microbiol 2010;53:640-5
   PubMed Web of Science ®Google Scholar
• Geissinger E, Bonzheim I, Roth S, CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk Lymphoma 2009;50:1010-16
   PubMed Web of Science ®Google Scholar
• de Leval L, Rickman DS, Thielen C, The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007;109:4952-63
   PubMed Web of Science ®Google Scholar
• Attygalle AD, Chuang SS, Diss TC, Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology 2007;50:498-508
   PubMed Web of Science ®Google Scholar
• Foss FM, Zinzani PL, Vose JM, Peripheral T-cell lymphoma. Blood 2011;117:6756-67
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Shovlin M, Pittaluga S, DA-EPOCH chemotherapy is highly effective in ALK-positive and ALK-negative ALCL: results of a prospective study of PTCL subtypes in adults. Blood 2011;118:704
   Web of Science ®Google Scholar
• Schmitz N, Trumper L, Ziepert M, Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418-25
   PubMed Web of Science ®Google Scholar
• Reimer P, Rudiger T, Geissinger E, Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27:106-13
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Vigorito E, Clare S, Requirement of bic/microRNA-155 for normal immune function. Science 2007;316:608-11
   PubMed Web of Science ®Google Scholar
• d'Amore F, Relander T, Lauritzsen GF, High-dose chemotherapy and autologuos stem cell transplantation in previously untreated peripheral T-cell lymphoma - final analysis of a large prospective multicenter study (NLG-T-01). Blood 2011;118:155-6
   Web of Science ®Google Scholar
• Piccaluga PP, Agostinelli C, Righi S, Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007;92:566-7
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E, Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-91
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Patti C, Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316-23
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chae YS, Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007;60:129-34
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, van Marwijk KM, Lugtenburg PJ, Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 2011;22:1595-600
   PubMed Web of Science ®Google Scholar
• d'Amore F, da Silva MG, Leppa S, First interim safety analysis of a phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood 2011;118:1755
   Web of Science ®Google Scholar
• Chen AI, McMillan A, Negrin RS, Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the stanford experience. Biol Blood Marrow Transplant 2008;14:741-7
   PubMed Web of Science ®Google Scholar
• Jantunen E, Wiklund T, Juvonen E, Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004;33:405-10
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006;134:202-7
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Caballero MD, Gutierrez A, High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003;14:1768-75
   PubMed Web of Science ®Google Scholar
• Schetelig J, Fetscher S, Reichle A, Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003;88:1272-8
   PubMed Web of Science ®Google Scholar
• Smith SD, Bolwell BJ, Rybicki LA, Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 2007;40:239-43
   PubMed Web of Science ®Google Scholar
• Blystad AK, Enblad G, Kvaloy S, High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001;27:711-16
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Munsell M, Yazji S, Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001;19:3766-70
   PubMed Web of Science ®Google Scholar
• Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003;120:978-85
   PubMed Web of Science ®Google Scholar
• Yang DH, Kim WS, Kim SJ, Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant 2009;15:118-25
   PubMed Web of Science ®Google Scholar
• Jagasia M, Morgan D, Goodman S, Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 2004;45:2261-7
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Zallio F, Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004;22:1460-8
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Milpied N, Buzyn A, Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008;26:2264-71
   PubMed Web of Science ®Google Scholar
• Stein H, Mason DY, Gerdes J, The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-58
   PubMed Web of Science ®Google Scholar
• Stein H, Lennert K, Feller AC, Mason DY. Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res 1984;42:67-147
   PubMed Web of Science ®Google Scholar
• Al-Shamkhani A. The role of CD30 in the pathogenesis of haematopoietic malignancies. Curr Opin Pharmacol 2004;4:355-9
   PubMed Web of Science ®Google Scholar
• Chiarle R, Voena C, Ambrogio C, The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23
   PubMed Web of Science ®Google Scholar
• Chiarle R, Martinengo C, Mastini C, The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 2008;14:676-80
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-4
   PubMed Web of Science ®Google Scholar
• Meani N, Alcalay M. Role of nucleophosmin in acute myeloid leukemia. Expert Rev Anticancer Ther 2009;9:1283-94
   PubMed Web of Science ®Google Scholar
• Zamo A, Chiarle R, Piva R, Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002;21:1038-47
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang P, Wu F, Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal 2012;24:852-8
   PubMed Web of Science ®Google Scholar
• Merkel O, Hamacher F, Laimer D, Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci USA 2010;107:16228-33
   PubMed Web of Science ®Google Scholar
• Matsuyama H, Suzuki HI, Nishimori H, miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood 2011;118:6881-92
   PubMed Web of Science ®Google Scholar
• Savage KJ, Harris NL, Vose JM, ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-504
   PubMed Web of Science ®Google Scholar
• Mathas S, Kreher S, Meaburn KJ, Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci USA 2009;106:5831-6
   PubMed Web of Science ®Google Scholar
• Piva R, Agnelli L, Pellegrino E, Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol 2010;28(9):1583-90
   PubMed Web of Science ®Google Scholar
• Piva R, Pellegrino E, Inghirami G. Identification and validation of the anaplastic large cell lymphoma signature. Adv Exp Med Biol 2007;604:129-36
   PubMed Web of Science ®Google Scholar
• Lamant L, de Reynies A, Duplantier MM, Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007;109:2156-64
   PubMed Web of Science ®Google Scholar
• Agnelli L, Mereu E, Pellegrino E, Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 2012;120:1274-81
   PubMed Web of Science ®Google Scholar
• Feldman AL, Dogan A, Smith DI, Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011;117:915-19
   PubMed Web of Science ®Google Scholar
• Costinean S, Zanesi N, Pekarsky Y, Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006;103:7024-9
   PubMed Web of Science ®Google Scholar
• O'Connell RM, Rao DS, Chaudhuri AA, Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008;205:585-94
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6
   PubMed Web of Science ®Google Scholar
• Simon A, Peoch M, Casassus P, Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 2010;151:159-66
   PubMed Web of Science ®Google Scholar
• Matutes E, Brito-Babapulle V, Swansbury J, Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991;78:3269-74
   PubMed Web of Science ®Google Scholar
• Keating MJ, Cazin B, Coutre S, Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002;20:205-13
   PubMed Web of Science ®Google Scholar
• Herling M, Khoury JD, Washington LT, A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004;104:328-35
   PubMed Web of Science ®Google Scholar
• Hopfinger G, Busch R, Eichhorst B, Sequential therapy of fludarabine, mitoxantrone and cyclophosphamide (Fmc) induction followed by alemtuzumab consolidation is effective and safe in patients with T-cell prolymphocytic leukemia (T-Pll) - results from a multicenter phase II trial of the German Cll Study Group. Ann Oncol 2011;22:124
   Web of Science ®Google Scholar
• Dearden CE, Matutes E, Cazin B, High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98:1721-6
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle V, Catovsky D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 1991;55:1-9
   PubMed Web of Science ®Google Scholar
• Mercieca J, Matutes E, Dearden C, The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994;12:2588-93
   PubMed Web of Science ®Google Scholar
• Pawson R, Dyer MJ, Barge R, Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997;15:2667-72
   PubMed Web of Science ®Google Scholar
• Dearden CE, Khot A, Else M, Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 2011;118:5799-802
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr, Schechter GP, Jaffe E, Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 1983;309:257-64
   PubMed Web of Science ®Google Scholar
• Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984 – 87). Br J Haematol 1991;79:428-37
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Utsunomiya A, Fukuda H, VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007;25:5458-64
   PubMed Web of Science ®Google Scholar
• Ishii T, Ishida T, Utsunomiya A, Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010;16:1520-31
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Utsunomiya A, Tobinai K, Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010;28:1591-8
   PubMed Web of Science ®Google Scholar
• Sieniawski MK, Lennard AL. Enteropathy-associated T-cell lymphoma: epidemiology, clinical features, and current treatment strategies. Curr Hematol Malig Rep 2011;6:231-40
   PubMedGoogle Scholar
• Raderer M, Troch M, Kiesewetter B, Second line chemotherapy in patients with enteropathy-associated T cell lymphoma: a retrospective single center analysis. Ann Hematol 2012;91:57-61
   PubMed Web of Science ®Google Scholar
• Sieniawski M, Angamuthu N, Boyd K, Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010;115:3664-70
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Biagi F, Gobbi PG, Corazza GR. How I treat enteropathy-associated T-cell lymphoma. Blood 2012;119:2458-68
   PubMed Web of Science ®Google Scholar
• Au WY, Pang A, Choy C, Quantification of circulating epstein-barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004;104:243-9
   PubMed Web of Science ®Google Scholar
• Au W, Intragumtornchai T, Nakamura S, Clinical and pathological differences between nasal and nasal-type NK/T cell lymphomas: a summary of 136 cases from the international T cell lymphoma (ITCL) project. Blood 2006;108:90A
   Web of Science ®Google Scholar
• Li YX, Yao B, Jin J, Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181-9
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol 2009;27:6027-32
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Marin B, Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117:1834-9
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Venkatraman E, Kris MG. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? J Natl Cancer Inst 2004;96:1117-19
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Yu CJ, Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27:5080-7
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011;364:775-6
   PubMed Web of Science ®Google Scholar
• Marks P, Rifkind RA, Richon VM, Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117:5827-34
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30:631-6
   PubMed Web of Science ®Google Scholar
• Dupuis J, Casasnovas RO, Morschhauser F, Early results of a phase Ib/II dose-escalation trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphomas (PTCL). Blood 2011;118:1148
   Web of Science ®Google Scholar
• Zain JM, Foss FM, Diefenbach CS, Preliminary results of an ongoing phase I trial of oral belinostat a novel histone deacetylase inhibitor in patients with lymphoid malignancies. Blood 2011;118:1585
   Web of Science ®Google Scholar
• Dueck G, Chua N, Prasad A, Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010;116:4541-8
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Broccoli A, Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma 2011;52:1585-8
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Hamlin PA, Portlock C, Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007;139:425-8
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Pro B, Pinter-Brown L, Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182-9
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Kim YH, Foss F, Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012;119:4115-22
   PubMed Web of Science ®Google Scholar
• Prince HM, Duvic M, Martin A, Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010;28:1870-7
   PubMed Web of Science ®Google Scholar
• Foss FM, Sjak-Shie N, Goy A, A phase II study of derdleukin diftitox (Ontak (R)) with CHOP chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: interim analysis. Blood 2006;108:696A-7A
   Web of Science ®Google Scholar
• Manfredi MG, Ecsedy JA, Meetze KA, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 2007;104:4106-11
   PubMed Web of Science ®Google Scholar
• Yang J, Ikezoe T, Nishioka C, AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007;110:2034-40
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Stejskal A, Cooke LS, Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-hodgkin lymphoma. Clin Cancer Res 2012;18:2210-19
   PubMed Web of Science ®Google Scholar
• Friedberg J, Mahadevan D, Jung J, Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of Aurora A Kinase (AAK), in patients (pts) with aggressive B- and T-cell non-hodgkin lymphoma (NHL). Blood 2011;118:46
   Web of Science ®Google Scholar
• Griffin CA, Hawkins AL, Dvorak C, Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999;59:2776-80
   PubMed Web of Science ®Google Scholar
• Arber DA, Sun LH, Weiss LM. Detection of the t(2;5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma. Hum Pathol 1996;27:590-4
   PubMed Web of Science ®Google Scholar
• Tuma RS. ALK gene amplified in most inflammatory breast cancers. J Natl Cancer Inst 2012;104:87-8
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Soda M, Togashi Y, RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81
   PubMed Web of Science ®Google Scholar
• Lin E, Li L, Guan Y, Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7:1466-76
   PubMed Web of Science ®Google Scholar
• Lamant L, Pulford K, Bischof D, Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000;156:1711-21
   PubMed Web of Science ®Google Scholar
• Powers C, Aigner A, Stoica GE, Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002;277:14153-8
   PubMed Web of Science ®Google Scholar
• Grzelinski M, Steinberg F, Martens T, Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia 2009;11:145-56
   PubMed Web of Science ®Google Scholar
• Puri N, Khramtsov A, Ahmed S, A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 2007;67:3529-34
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9
   PubMed Web of Science ®Google Scholar
• Heuckmann JM, Holzel M, Sos ML, ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors. Clin Cancer Res 2011;17:7394-401
   PubMed Web of Science ®Google Scholar
• Yamada T, Takeuchi S, Nakade J, Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. Clin Cancer Res 2012;18(13):3592-602
   PubMed Web of Science ®Google Scholar
• Galkin AV, Melnick JS, Kim S, Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007;104:270-5
   PubMed Web of Science ®Google Scholar
• Li N, Michellys P-Y, Kim S, Activity of a potent and selective phase I ALK inhibitor LDK378 in naive and crizotinib-resistant preclinical tumor models. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. 10 edition. 2011
   Google Scholar
• Piva R, Chiarle R, Manazza AD, Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 2006;107:689-97
   PubMed Web of Science ®Google Scholar
• Tripathy R, McHugh RJ, Ghose AK, Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group. Bioorg Med Chem Lett 2011;21:7261-4
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Tsukaguchi T, Hiroshima S, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-90
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, A phase II study of SGN-30 (anti-CD30 mAb) in hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9
   PubMed Web of Science ®Google Scholar
• Duvic M, Reddy SA, Pinter-Brown L, A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 2009;15:6217-24
   PubMed Web of Science ®Google Scholar
• Duvic M. Improved understanding of peripheral T-cell lymphomas. Oncology (Williston Park) 2010;587:592-3
   Google Scholar
• Younes A, Bartlett NL, Leonard JP, Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-6
   PubMed Web of Science ®Google Scholar
• Fanale MA, Forero-Torres A, Rosenblatt JD, A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012;18:248-55
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Musuraca G, Tani M, Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:4293-7
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Kang HJ, Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 2008;19:2079-83
   PubMed Web of Science ®Google Scholar
• Delmer A, Fitoussi O, Gaulard P, A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial. J Clin Oncol 2009;27; abstract no. 8554
   Web of Science ®Google Scholar
• Wang L, Lawrence MS, Wan Y, SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497-506
   PubMed Web of Science ®Google Scholar
• Marchi E, Kalac M, Bongero DC, Combination of epigenetic agents synergistically reverse the malignant phenotype in models of T-cell lymphoma. Blood 2011;118:1173
   Web of Science ®Google Scholar
• Tang T, Allen G, Koo GC, Gene expression profiling identifies the JAK/STAT and NF kappa B pathways to be important in peripheral T-cell lymphomas and natural-killer T-cell lymphomas. Blood 2011;118:1142
   Web of Science ®Google Scholar